SAB Biotherapeutics (SABS) Receives Grant for SAB-142 Assessment
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowOn July 7, SAB Biotherapeutics Inc. (NASDAQ: SABS) received a research grant from Breakthrough T1D to support the PRISE-hATG clinical assessment of SAB-142 in Stage 3 type 1 diabetes patients. This assessment focuses on individuals diagnosed between 100 days and 2 years and aims to evaluate SAB-142's effectiveness in preserving C-peptide levels and regulating immune responses. Eliana Merle from Barclays has rated the stock as Overweight with a target price of $13, suggesting over 240% upside potential. The Phase 2b data for this immunotherapy is expected in the second half of 2027, which could be significant for investors.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
